Form 4: Amgen CFO Sells Shares for Tax Obligations

Amgen's EVP & CFO, Peter H. Griffith, disposed of 5,748 shares of common stock to cover tax liabilities at a price of $366.21 per share.

Summary

• Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc. (AMGN), reported a disposition of common stock.
• The transaction, executed on March 16, 2026, involved the sale of 5,748 shares at a price of $366.21 per share.
• The disposition was coded as 'F', indicating a transaction to cover tax liability by the issuer, likely related to the vesting of equity awards.
• Following this transaction, Griffith beneficially owns 49,001 shares of Amgen common stock.
• The reported shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• Dividend Equivalents are credited to unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, with cash for any fractional shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine disposition of shares to cover tax obligations, which is a common occurrence for executives receiving equity compensation and does not reflect a change in sentiment towards the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide broader industry context. This specific filing reflects a common practice for executives to cover tax obligations arising from equity awards, often pre-planned under Rule 10b5-1.

Related Party Transactions

• Disposition of 5,748 shares to Amgen Inc. to cover tax liabilities related to equity awards.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related disposition, not a discretionary market sale.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing reports a routine disposition of shares by an executive to cover tax obligations, which is a common and expected event in executive compensation. It does not provide new information that would warrant a change in investment thesis or a strong buy/sell recommendation. Therefore, a 'hold' recommendation is appropriate as the fundamental outlook for Amgen remains unchanged based on this filing.

Keywords

Amgen, AMGN, Peter H. Griffith, Form 4, Insider Transaction, Stock Sale, Tax Liability, EVP & CFO, Common Stock, Dividend Equivalents, Equity Incentive Plan